Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

PCI Announces Capital Investment in Rockford Facilities

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Leading pharmaceutical packaging firm investing in support of business growth.

Packaging Coordinators Inc (PCI) has announced further investment in its Rockford facilities in support of business growth and expansion.

The company acquired AndersonBrecon Inc. in May of this year and is adding additional equipment capacity and facilities infrastructure through capital investment, as well as hiring in support of business growth.

The company provides packaging services for pharmaceutical and healthcare products, working with leading Pharmaceutical and Biotech companies to bring lifesaving medicines to patients.

PCI operates 9 facilities in the greater Rockford, Illinois area totaling over 1 million square feet and employing over 1,300 highly trained associates.

PCI is owned by an entity formed by affiliates of lead investor Frazier Healthcare, a leading provider of growth equity and venture capital to high growth and emerging healthcare service and Biotech companies.

Continued Growth and Expansion
PCI’s Rockford location is experiencing its fourth straight year of significant growth. The company is experiencing substantial growth in 2013, which is anticipated to continue in 2014 and beyond.

In support of this growth, PCI has hired approximately 160 associates since January of 2012. Positions added include hourly, skilled labor, as well as management.

In addition to hiring, the company is looking to support new business by expanding its machine capacity, warehousing, and facilities infrastructure. PCI has added multiple blister packaging and bottling lines to meet increased demand in Ethical (prescription) and Over-the-Counter pharmaceutical markets and plans additional investment in this area.

The company is also investing in support of growth markets including commercial Biotech medicines and Clinical (Investigational) medicines.

Capital investments include expansion of on-site refrigerated Cold Chain storage capacity at 2 – 8° Celsius, -20° Celsius, and -80° Celsius.

A History Of Investment
The company opened a stand-alone potent compound packaging facility in 2010 and a new Clinical (Investigational) medicines packaging facility in 2011.

PCI’s largest Rockford facility, located at the Greater Rockford Industrial Park, was most recently expanded in 2008 and comprises over 720,000 square feet.

PCI’s North American and European sites feature state-of-the-art packaging facilities and cutting edge technologies, supporting very recognizable brands in the global healthcare market.

The company packages medicines destined for patients spanning over 100 countries across the globe. PCI’s headquarters in Philadelphia, PA employs approximately 475 associates.

A facility in Woodstock, IL employs approximately 125 additional associates. PCI’s domestic locations are complemented by four packaging sites in Wales, which currently employ approximately 300 associates, mainly in support of pharmaceutical products for the European region.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Definitive Agreement to Acquire Penn Pharma
PCI’s expands service offering with acquisition of Penn Pharma.
Thursday, July 31, 2014
Peter Belden Named General Manager of PCI Rockford Facilities
Belden returns to PCI North America to manage Rockford, IL operations.
Monday, September 02, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Antibiotics on Our Plates 'Could Lead to Health Catastrophe'
Two medical experts from The University of Queensland are urging China to curb its use of antibiotics in animals to avoid what could be a ‘major health catastrophe’ for humans.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos